ECE2015 Eposter Presentations Pituitary: clinical (121 abstracts)
Acrostart: Spanish retrospective study to determine the timeframe to achieve hormonal normalisation with initial Somatuline Autogel® treatment in acromegaly patients in routine clinical practice
Cristina Álvarez Escolá 1 , Eva María Venegas Moreno 2 , Juan Antonio García Arnés 3 , Concepción Blanco Carrera 4 , Mónica Marazuela Azpiroz 5 , María Ángeles Gálvez Moreno 6 , Edelmiro Menéndez Torre 7 , Javier Aller Pardo 8 , Isabel Salinas Vert 9 , Eugenia Resmini 10 , Elena María Torres Vela 11 , María Ángeles Gonzalo Redondo 12 , Ricardo Vílchez Joya 13 , María Paz de Miguel Novoa 14 , Irene Halperín Rabinovich 15 , Concepción Páramo Fernández 16 , Antonio Miguel Picó Alfonso 17 , Sara Arroyo 18 , Francesc Pérez 18 & Eva Pineda 18
1Hospital Universitario La Paz, Madrid, Spain; 2Hospital Universitario Virgen del Rocío, Sevilla, Spain; 3Hospital Regional Universitario Carlos Haya, Málaga, Spain; 4Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; 5Hospital Universitario de La Princesa, Madrid, Spain; 6Hospital Universitario Reina Sofía, Córdoba, Spain; 7Hospital Universitario Central de Asturias, Oviedo, Spain; 8Hospital Universitario Puerta de Hierro, Majadahonda, Spain; 9Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 10Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 11Hospital Universitario San Cecilio, Granada, Spain; 12Fundación Jiménez Díaz, Madrid, Spain; 13Hospital General Virgen de las Nieves, Granada, Spain; 14Hospital Clínico San Carlos, Madrid, Spain; 15Hospital Clínic Provincial, Barcelona, Spain; 16Complejo Hospitalario Xeral-Cies de Vigo, Vigo, Spain; 17Hospital General Universitari d’Alacant, Alacant, Spain; 18IPSEN Pharma, L’Hospitalet de Llobregat, Barcelona, Spain.
Introduction: This study aimed to determine the timeframe to achieve hormonal normalization considering dosing patterns of Somatuline Autogel (SOM, lanreotide) used in clinical practice.
Methods: From March 2013 to October 2013 clinical data from 62 patients with active acromegaly treated with SOM for ≧4 months who achieved hormonal control (GH levels <2.5 ng/ml and/or normalised IGF1 on ≧two evaluations) at 17 Spanish hospitals were collected into a database. Primary objective was to determine the timeframe from initiating SOM treatment to hormonal normalisation. Secondary objectives included use of health resources, tumour size control, patient satisfaction and adherence.
Results: Non-compliance excluded five patients. Median age of 57 patients was 64 years (23–90), 21 (36.8%) were male, 35 (61.4%) had macroadenoma, 39 (68.4%) had undergone surgery, 14 (24.6%) had received radiotherapy. Median hormonal values at start of SOM treatment were GH: 2.6 ng/ml (95%CI 2.6–7.4), IGF1: 1.6xULN (95% CI 1.6–2.1). SOM 120 mg was the most frequent initial dose (51% patients), with prolonged interval use (≧6 weeks) in 44% patients. Main starting regimens were 60 mg per 4 weeks (n=13), 90 mg per 4 weeks (n=6), 120 mg per 4 weeks (n=13), 120 mg per 6 weeks (n=6), 120 mg per 8 weeks (n=9). Median length of SOM treatment was 68 months (7–205). Hormonal control was achieved in 4.9 months (95%CI 7.9–20.1). 13 (22.8%) patients managed injections without assistance of health care nurses: 8 (14.0%) were able to self-inject and 5 (8.8%) had injections administered by close relatives. Median number of specialist physician visits until hormonal control was 3 (95%CI 4–10). During SOM treatment tumour shrinkage up to 46.7% was reported in ten patients with available information. 51 (89.5%) patients were ‘satisfied’/‘very satisfied’ with SOM treatment and 49 (86.0%) patients did not miss any doses.
Conclusion: Real-life treatment with SOM led to a fast hormonal control in acromegaly responder patients, with a high treatment adherence and treatment satisfaction, despite disparity of SOM starting doses and interval dosing.
Disclosure: This study was sponsored by IPSEN PHARMA, S.A.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more